Investment Thesis
Savara is a pre-revenue or severely distressed pharmaceutical company with zero reported revenue, massive operating losses of -$39M, and negative free cash flow of -$33.1M annually. With only $38.8M in cash reserves against a burn rate of ~$33M per year, the company faces critical liquidity concerns with approximately 14 months of runway remaining.
Strengths
- Strong liquidity position with 13.47x current ratio and quick ratio indicating ability to meet short-term obligations
- Conservative capital structure with 0.17x debt/equity ratio and only $30.1M long-term debt limiting financial distress risk
- Stockholders' equity of $176M provides asset backing, though severely impaired by operational losses
Risks
- Zero revenue indicates no commercial viability or complete product failure requiring urgent pipeline advancement
- Negative operating cash flow of -$33M annually with limited runway of approximately 14 months at current burn rate
- Unable to cover interest expenses from operations (interest coverage ratio of -179.7x) indicating dependency on equity or asset sales
- Sector-specific risk: pharmaceutical development dependency on successful FDA approvals and market adoption with uncertain timelines
- Dilution risk evident in worsening EPS (-0.15, -10.4% YoY) suggesting multiple capital raises
Key Metrics to Watch
- Monthly cash burn rate and remaining runway to avoid insolvency
- Revenue generation milestones and product pipeline approval status
- Operating cash flow inflection points indicating path to profitability
- Debt covenant compliance and refinancing requirements
Financial Metrics
Revenue
0.0
Net Income
-37.3M
EPS (Diluted)
$-0.15
Free Cash Flow
-33.1M
Total Assets
221.6M
Cash
38.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-21.2%
ROA
-16.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
13.47x
Quick Ratio
13.47x
Debt/Equity
0.17x
Debt/Assets
20.6%
Interest Coverage
-179.68x
Long-term Debt
30.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T09:16:46.678897 |
Data as of: 2026-03-31 |
Powered by Claude AI